Humacyte (HUMA) Liabilities and Shareholders Equity (2020 - 2026)

Humacyte (HUMA) has 7 years of Liabilities and Shareholders Equity data on file, last reported at $110.6 million in Q1 2026.

• Liabilities and Shareholders Equity for Q1 2026 came in at $110.6 million, down 31.99% year-over-year; the trailing twelve-month figure through Mar 2026 was $457.2 million (down 17.39% YoY), and the FY2025 annual result was $116.4 million, down 15.6% from the prior year.
• Liabilities and Shareholders Equity declined to $110.6 million in Q1 2026 per HUMA's latest filing, from $116.4 million in the prior quarter.
• Over five years, Liabilities and Shareholders Equity peaked at $264.5 million in Q1 2022 and troughed at $91.5 million in Q3 2025.
• A 5-year average of $161.3 million and a median of $149.4 million in 2023 frame the typical range for Liabilities and Shareholders Equity.
• The sharpest annual moves came in 2022 and 2023: Liabilities and Shareholders Equity soared 162.71% in 2022, then plunged 37.24% in 2023.
• A 5-year view of Liabilities and Shareholders Equity shows it stood at $204.3 million in 2022, then sank by 37.24% to $128.2 million in 2023, then gained by 7.53% to $137.9 million in 2024, then fell by 15.6% to $116.4 million in 2025, then dropped by 4.99% to $110.6 million in 2026.
• Business Quant data shows HUMA's Liabilities and Shareholders Equity at $110.6 million in Q1 2026, $116.4 million in Q4 2025, and $91.5 million in Q3 2025.